Pancreatic cancer is the third most common cause of cancer-related deaths in the United States, despite being designated an orphan disease, and the seventh most common cause of cancer-related deaths in industrialized countries worldwide. Greater than 90% of pancreatic cancer patients have pancreatic ductal adenocarcinoma (PDA). Because of the location of the pancreas deep within the abdomen, PDA is rarely detected in its early stages and most patients have metastatic disease (Stage 4) at the time of diagnosis. Five-year survival in metastatic pancreatic cancer patients is less than 3%. The disease is increasing in incidence, and recent advances in treatment have provided only modest benefits in median overall survival in pivotal trials of approved drugs. PDA is characterized by elevated levels of polyamines, natural components for growth of all mammalian cells. Panbela is studying the effect of SBP-101, a polyamine metabolic inhibitor, in disrupting cancer cell metabolism when added to standard of care treatment regimens for pancreatic cancer.